→ UCSF hired Harold “Barry” Sellick as its new vice chancellor to nurture inventions and bring new products to the market at a more advanced stage. And to that end he will supervise proof-of-concept studies for a range of drugs and devices.
→ Teva announced the exit of longtime CFO Eyal Desheh, feeding into speculation regarding the top-to-bottom reorganization of the company after generic drug prices began to erode.
→ New York-based Rgenix named Novartis vet Roger Waltzman as its chief medical officer. The biotech works on antibody therapies for cancer.
→ In a surprise move for even the most hard-bitten company observers, Sarepta CEO Ed Kaye announced during Thursday’s quarterly call with analysts that he’ll be leaving later this year.
→ Troubled Ophthotech is moving CEO David Guyer to the executive chairman’s role while promoting CFO Glenn P. Sblendorio to the CEO spot.
→ Karolinska Development announced that Chairman Bo Jesper Hansen and CEO Jim Van Heusden have decided to step down. Viktor Drvota has been promoted to CEO.
→ Biogen vet Michael Cloonan has joined Sage Therapeutics $SAGE as its new chief business officer. In other moves, Christopher Silber was named senior vice president, clinical development, Paul Hodgkins is now vice president, health economics and outcomes research and value demonstration and Frank Sanders was tapped as vice president, sales & marketing. In addition, Amy Schacterle, has been promoted to senior vice president, regulatory affairs and quality assurance.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription